Targeted therapy progress of indolent B-cell lymphoma
10.3760/cma.j.issn.1009-9921.2018.01.006
- VernacularTitle:惰性B细胞淋巴瘤的靶向治疗研究进展
- Author:
Chunli YANG
1
;
Liqun ZOU
Author Information
1. 四川大学华西医院肿瘤中心
- Keywords:
Lymphoma;
B-cell;
Indolent;
Targeted therapy
- From:
Journal of Leukemia & Lymphoma
2018;27(1):20-23
- CountryChina
- Language:Chinese
-
Abstract:
Indolent B-cell lymphoma is still an incurable disease. However, with the further understanding of the pathogenesis of B-cell lymphoma in recent years, the number of treatment drugs and protocols for indolent B-cell lymphoma is increasing, including targeted drugs CD20 monoclonal antibody, BTK inhibitors, immunosuppressive agents, proteasome inhibitors, immune checkpoint inhibitors, which may have effects on the future treatment strategies. This paper summarizes the key clinical trials of targeted therapies for indolent B-cell lymphoma according to the 59th American Society of Hematology Annual Meeting.
